RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Bridging Integrator 3 (BIN3) Downregulation Predicts a Poor Prognosis in Patients with Esophagus Carcinoma: A Study based on TCGA Data.
Bridging Integrator 3 (BIN3) Downregulation Predicts a Poor Prognosis in Patients with Esophagus Carcinoma: A Study based on TCGA Data.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些结果提示 BIN3 可能是 ESCA 的一个潜在预后生物标志物。BIN3 在 ESCA 中发挥抑癌作用,这与 ESCA 的免疫浸润显著相关。
桥接整合因子3(BIN3)已被报道在某些肿瘤中发挥关键作用。然而,关于BIN3在食管癌(ESCA)中的作用及临床价值知之甚少。本研究旨在探讨BIN3在ESCA患者中的病理和预后作用。
通过综合分析ESCA中与总生存期(OS)、疾病特异性生存期(DSS)和无进展间期(PFI)相关的差异表达基因,筛选并鉴定了与ESCA患者预后显著相关的基因。利用癌症基因组图谱(TCGA)和GTEx数据库对BIN3的表达、病理特征相关性及亚组总生存期分析进行了研究。此外,通过GO-KEGG富集分析和基因集富集分析(GSEA)分析了BIN3涉及的潜在信号通路。通过TIMER和ssGSEA分析了BIN3在ESCA中与免疫浸润的相关性。通过western blot验证了BIN3对上皮-间质转化(EMT)的影响。
从ESCA患者中与总生存期(OS)、疾病特异性生存期(DSS)和无进展间期(PFI)相关的三个基因簇中,鉴定出两个与ESCA患者预后相关的差异表达基因。与正常组织相比,ESCA中BIN3 mRNA水平显著降低(p < 0.05)。ESCA中BIN3表达降低与临床分期(p = 0.015)、T分期(p < 0.05)、组织学类型(p < 0.001)、年龄(p < 0.05)和性别(p < 0.05)显著相关。观察到BIN3高表达的ESCA患者与T分期(T3 & T4)、年龄(<=60)、性别(男性)、主要治疗结局(PD)和柱状化生(无)的有利OS相关。GO-KEGG富集分析显示BIN3参与内吞作用。GSEA显示BIN3中富集了若干通路,如黏蛋白的O连接糖基化、PID HNF3B通路、biocarta TFF通路、WP孕烷X受体通路、reactome β细胞发育调控、WP尿素循环及相关通路等。BIN3与T细胞(p < 0.001)、Tregs(p < 0.001)、B细胞(p < 0.001)、NK细胞(p < 0.001)和巨噬细胞M2(p < 0.001)的浸润水平显著相关。此外,BIN3过表达抑制ESCA细胞系TE-1中N-cadherin表达并促进E-cadherin表达。
Bridging integrator 3 (BIN3) has been reported to play a key role in certain tumors. Nevertheless, little is known about the role and clinical value of BIN3 in esophagus carcinoma (ESCA). This study aimed to investigate the pathological and prognostic role of BIN3 in ESCA patients.
Genes significantly correlated with the prognosis of ESCA patients were screened and identified by comprehensive analysis of differentially expressed genes associated with overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI) in ESCA. The expression of BIN3, pathological features correlation and subgroup overall survival analysis were performed using The Cancer Genome Atlas (TCGA) and GTEx databases. Moreover, the potential signaling pathways in which BIN3 was involved were analyzed by GO-KEGG enrichment analysis and gene set enrichment analysis (GSEA). Immune infiltrates correlation of BIN3 in ESCA was performed by TIMER and ssGSEA. The influence of BIN3 on epithelial-mesenchymal transition (EMT) was validated by western blot.
There were two differentially expressed genes related to the prognosis of ESCA patients, which were identified from three gene clusters associated with overall survival (OS), diseasespecific survival (DSS) and progression-free interval (PFI) in ESCA patients. The BIN3 mRNA level was found to be significantly decreased in ESCA compared to normal tissues (p < 0.05). The decreased expression of BIN3 in ESCA was significantly correlated with the clinical stage (p = 0.015), T stage (p < 0.05), histological type (p < 0.001), age (p < 0.05) and gender (p < 0.05). ESCA patients with high BIN3 expression were observed to be correlated with T stage (T3 & T4), age (<=60), gender (male), primary therapy outcome (PD) and columnar metaplasia (No) of favorable OS. GO-KEGG enrichment analysis revealed that BIN3 was involved in endocytosis. GSEA showed that several pathways were enriched in BIN3, such as O linked glycosylation of mucins, PID HNF3B pathway, biocarta TFF pathway, WP pregnane X receptor pathway, reactome regulation of beta cell development, WP Urea cycle and associated pathways and others. BIN3 was significantly related to the infiltration level of T cells (p < 0.001), Tregs (p < 0.001), B cells (p < 0.001), NK cells (p < 0.001), and macrophage M2 (p < 0.001). In addition, BIN3 overexpression inhibited N-cadherin expression and promoted E-cadherin expression in ESCA cell lines TE-1.
These results suggest that BIN3 might be a potential prognostic biomarker in ESCA. BIN3 functions as a tumor-suppressor role in ESCA, which is significantly associated with the immune infiltration of ESCA.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。